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Summary
Opioid misuse is now considered a major public health epidemic in North America, with substantial social and
financial consequences. As well as socio-economic and commercial drivers, modifiable risk-factors that have
resulted in this crisis have been identified. The purpose of this study was to identify whether, within England,
modifiable drivers for persistent postoperative opioid use were present. This was a retrospective cohort study of
practice at 14 National Health Service hospitals across England. Data were collected retrospectively and
validated for adult patients undergoing elective intermediate and major or complex major general surgical
procedures between 1 and 31 March 2019. Of the 509 patients enrolled from 14 centres, 499 were included in
the data analysis. In total, 31.5% (157/499) patients were in the intermediate surgery cohort and 68.5% (342/
499) were in the major or complex major surgery cohort, with 21.0% (33/157) and 21.6% (74/342) discharged
with opioid medicines to be taken at regular intervals, respectively. There were similar median oral morphine
equivalent doses prescribed at discharge.Of patients prescribed regular opioidmedicines, 76.6% (82/107) had
a specified duration at discharge. However, 72.9% (78/107) had no written deprescribing advice on discharge.
Similarly, of patients prescribed ‘when required’ opioids, 59.6% (93/156) had a specified duration of their
prescription and 33.3% (52/156) were given written deprescribing advice. This study has identified a pattern of
poor prescribing practices, a lack of guidance and formal training at individual institutions and highlights
opportunities for improvement in opioid-prescribingpractices within England.
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Introduction
Opioid misuse is now considered a major public
health epidemic in North America, with substantial
social and financial consequences [1–3]. In 2016, it
was estimated that the combined effect of the opioid
epidemic on healthcare, labour and criminal justice
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costs in the USA was £67 billion ($92 billion, €75
billion) [3]. Up to 2017, there have been at least
600,000 deaths from prescribed opioids in the USA,
and another 180,000 were predicted to occur by the
end of 2020 [1]. In addition, up to 75% of heroin-
dependent users started their addiction with the use
of prescription opioids [4].
The causes of this healthcare crisis are multifactorial [2,
5–12]. As well as socio-economic and commercial drivers, a
multitude of modifiable risk-factors have been previously
reported [8, 9]. Some of these more significant risk-factors
include the treatment of acute pain [6, 13]; the use of
modified-release opioid formulations [10]; repeat or refill
opioid prescriptions [10]; excessive prescription in terms of
duration and quantity [5]; and opioid diversion or poor
opioid disposal, given that up to 17% of non-medical users
obtain opioids fromdiversion of prescriptions [14].
Opioid use and misuse are increasing in the UK [13, 15–
17], and surgery has recently been identified as a risk-factor
for persistent opioid use [13]. In 2015, opioids were
prescribed to 5% of all patients on the Clinical Practice
Research Datalink that includes 50 million patients across a
network of general practices across the UK [17]. In 2012, 18%
of the Scottish population were prescribed an opioid, with
prescription rates varying according to regional and
sociodemographic factors [16]. A study demonstrated that
between 1998 and 2016, opioid prescriptions increased by
34% in England and the total oral morphine equivalency
increased by 127% to 431 g per 1000 population per year
[15]. Thus, as well as an increase in the number of opioid
prescriptions, the dose of prescribed opioids consumed in
the UK is also increasing. Consequently, the UK’s Medicines
and Healthcare products Regulatory Agency has released a
drug safety update on strategies to mitigate the harm from
opioid medicines and the risk of addiction [18]. This
compliments international guidance which recommends that
all patients discharged home with a newly prescribed opioid
analgesic should receive advice on the duration of the
course of opioids and that they should also receive written
deprescribing advice [8]. However, no study has been
undertaken so far on postoperative discharge prescribing
practices in the UK, and the drivers for persistent
postoperative opioid use in the UK remain under-
investigated.
We performed a retrospective multicentre study to
provide an overview of current practice in England on
analgesic medicine prescribing at discharge after surgery,
with the aim of determining whether modifiable drivers for
subsequent persistent postoperative opioid use were
present.
Methods
This was a retrospective observational cohort study of
practice at 14 NHS hospitals across England (online
Supporting Information Table S1). Data were collected
retrospectively and validated for adult patients undergoing
elective general surgical procedures between 1 and 31
March 2019.
The study was a service evaluation of current practice of
postoperative opioid-prescribing at discharge; thus, there
was no need for formal ethical approval or for obtaining
informed consent. The study was prospectively registered
and approved locally at each participating site under the
supervision of a named consultant surgeon or anaesthetist.
Project registration numbers for each of the 14 sites are
listed in online Supporting Information Table S1. Audit
information governance standards were adhered to in
collating data. All data were anonymised and no patient-
identifiable informationwas transferred between sites.
All bar one study site used a combination of digital and
paper records for data collection (one study site was fully
dependent on paper records). Patient identification and
data collection were performed by teams at each individual
site. These consisted of a consultant and trainee lead
responsible for data verification, and a number of
collaborators consisting of doctors of varying grades and
specialist nurses trained in prescribing. Admission
medicines were identified from either pre-operative
proformas or medical clerking records. Discharge
medicines were recorded from discharge prescriptions and
discharge letters. Data were collected on consecutive
patientsmeeting inclusion criteria.
Patients older than 16 years of age at the time of
surgery were included if they were undergoing elective
general surgery. Procedures were classified as
‘intermediate’ and ‘major or complex major’ according to
the Bupa schedule of procedures [19]. Patients
undergoing day-case surgery and emergency or re-
operative surgery were not included as it was felt it would
not be as easy to clearly identify all consecutive cases at
each site, and that emergency patients were more likely
to have a complicated surgical course which may impact
their analgesic regimen.
Outcomes of interest included prescribed oral
analgesia before index admission and detail on the
prescription and type of postoperative analgesia at
discharge, including dosage, frequency, duration and
written evidence of deprescribing advice. Given emerging
advice on compound analgesics and modified-release
opioid preparations [20, 21], the number of patients
prescribed these either as regular or when required, and the
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evidence of dose duration and deprescribing advice were
quantified. The oral morphine equivalent doses for opioid
prescriptions at discharge were calculated using the
electronic opioid calculator developed by the Faculty of
Pain Medicine, Australian and New Zealand College of
Anaesthetists [22]. Data were also collected through
consultant and trainee site leads on institutional practices,
policies, guidelines and training strategies for opioid
prescription at discharge from each of the 14 participating
sites.
Age at the time of surgery was categorised into three
groups: 18–64; 65–74; and ≥ 75 years, to allow exploration
of differences by World Health Organization definition of
young (< 65 years) and elderly (≥ 65 years). Sex was
recorded as male or female. Comorbidity was determined
using the Charlson comorbidity index [23] and categorised
as 0, 1–2 and ≥ 3. Information on additional pre-existing
comorbidities including arthritides [24], malignancy and
mental health disorders [25] which may be associated with
regular analgesia prescription or addictive personalities
were coded separately.
Length of stay was calculated from the date of
admission to the recorded date of discharge. Medicine
history including over the counter medicines was obtained.
Analgesic medicines were coded as non-opioids; non-
steroidal anti-inflammatory drugs; weak opioids; strong
opioids; and analgesic adjuncts prescribed pre-operatively
(before admission) and postoperatively (at discharge from
hospital) (online Supporting Information Table S2). Data
were collected on baseline patient baseline characteristics
and details of surgery.
The pooled anonymised data from included sites
were analysed using Stata V16 (StataCorp, College
Station, TX, USA). Included patients were stratified by
the magnitude of the surgical intervention into two
cohorts: intermediate surgery cohort (all intermediate
procedures) and major surgery cohort (which included
participants undergoing either major or complex major
surgery). Descriptive statistics were used to report the
baseline characteristics of the intermediate and major
surgery cohorts. Fisher’s exact and Chi squared (v2) tests
were used to compare categorical variables as
appropriate. The Mann–Whitney U-test was used for
within group comparisons and the Wilcoxon signed
ranks test for comparisons between groups. Frequency
and proportions were used to describe the number of
patients prescribed pre-operative (before admission) and
postoperative (at discharge) analgesia stratified by
analgesia type. For each, data on dose duration for
each analgesic medicine and whether deprescribing
advice was provided on the discharge prescription were
quantified. Univariable and multivariable logistic
regression models were used to explore factors that
predicted opioid prescription at discharge. In all
analyses, significance was set at the 95% level and
differences were considered significant if the p value
was < 0.05.
Results
We enrolled 509 patients from 14 centres. Ten patients
were not included: nine died and one had missing paper
medical records (online Supporting Information
Figure S1), leaving 499 patients analysed. Each centre
contributed a median (IQR [range]) 28 (22–42 [14–79])
patients. Baseline characteristics are summarised in
Table 1.
One hundred and nine (69.4%) patients in the
intermediate and 238 (69.6%) patients in the major or
complex major surgery cohorts were not taking any
analgesic medicines before admission for surgery. There
was no difference in the number of patients prescribed pre-
admission analgesia between the two cohorts (p = 0.971,
Table 2).
Patients received various combinations of discharge
medicines. These variations included type of medication,
duration and whether to take ‘when required’ or at regular
intervals. Of patients prescribed regular opioid medicines,
76.6% (82/107) had a specified duration documented at
discharge. However, 72.9% (78/107) had no written
deprescribing advice on discharge. Similarly, of patients
prescribed ‘when required’ opioids, 59.6% (93/156) had a
specified duration of their prescription and 33.3% (52/156)
were givenwritten deprescribing advice.
Variations in admission and discharge oral morphine
equivalent doses in opioid na€ıve and opioid tolerant
patients, along with a comparison between patients
undergoing intermediate and major or complex major
surgery are shown in Figure 1.
Only 15 patients were prescribed the combined
preparation of co-codamol either as regular or ‘when
required’ analgesia, all of whom were in the
intermediate surgery group. Of these, 11 (73.3%) had
specified prescription duration and four (26.7%) had
deprescribing advice. Modified-release morphine
sulphate was prescribed to 28 patients who were
previously opioid na€ıve, of whom 10 (35.7%) had no
prescription duration specified and 18 (64.3%) had no
deprescribing advice given. Modified-release oxycodone
was prescribed to 19 patients, 16 (84.2%) of whom had
a duration of prescription specified and 10 (52.6%) had
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deprescribing advice. Immediate-release oxycodone was
prescribed ‘when required’ to 30 patients, of whom 22
(73.3%) had a specified duration and 17 (56.7%) had
deprescribing advice (Table 3).
Patients aged ≥ 65 years were less likely to be
discharged home on oral opioids than younger
patients on both univariable and multivariable analysis
(Table 4). None of the other variables analysed had a
statistically significant impact on opioid prescriptions at
discharge.
Institutional practices, policies, guidelines and training
strategies for opioid prescription at discharge in the 14
centres are summarised in Table 5.
Discussion
This is the first study from England (and the UK) to examine
opioid-prescribing practices at discharge after surgery, with
the particular goal of determining whether modifiable
drivers for subsequent persistent postoperative opioid use
were present. Data were collected inMarch 2019, before the







n = 342 p value
Sex
Female 230 (46.1%) 67 (42.7%) 163 (47.7%) 0.299
Male 269 (53.9%) 90 (57.3%) 179 (52.3%)
Age
18–64 y 244 (48.9%) 88 (56.1%) 156 (45.6%) 0.045
65–74 y 146 (29.3%) 44 (28.0%) 102 (29.8%)
≥ 75 y 109 (21.8%) 25 (15.9%) 84 (24.6%)
Charlson comorbidity index
0 164 (32.9%) 80 (51.0%) 84 (24.6%) < 0.001
1–2 198 (39.7%) 44 (28.0%) 154 (45.0%)
≥ 3 137 (27.4%) 33 (21.0%) 104 (30.4%)
Arthritis
Yes 77 (15.4%) 23 (14.7%) 54 (15.8%) 0.743
No 422 (84.6%) 134 (85.3%) 288 (84.2%)
Mental health diagnoses
Yes 48 (9.6%) 20 (12.7%) 28 (8.2%)
No 451 (90.4%) 137 (87.3%) 314 (91.8%) 0.109
Other (pain related)
Yes 72 (14.4%) 34 (21.7%) 38 (11.1%) 0.002
No 427 (85.6%) 123 (78.3%) 304 (88.9%)
Malignancy status
Benigndisease 254 (51.1%) 142 (90.4%) 112 (32.9%) < 0.001
Cancer 243 (48.9%) 15 (9.6%) 228 (67.1%)
Pre-operative analgesicmedicines
Regularmedicines 152 (30.5%) 48 (30.6%) 104 (30.4%) 0.971
Nomedicines 347 (69.5%) 109 (69.4%) 238 (69.6%)
Surgical approach
Open 283 (56.7%) 115 (73.3%) 168 (49.1%) < 0.001
Minimally invasive 216 (43.3%) 42 (26.7%) 174 (50.9%)
Length of stay
0–4 days 211 (42.3%) 105 (66.9%) 106 (31.0%)
5–7 days 130 (26.0%) 23 (14.6%) 107 (31.3%)
≥ 8 days 158 (31.7%) 29 (18.5%) 129 (37.7%) < 0.001
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publication of a study which demonstrated that surgery is a
risk-factor for persistent postoperative opioid use in the UK
[13]. This also predated international guidelines on the
prevention of opioid-related harm in surgical patients [8, 26]
and the drug safety update on opioids released by the
Medicines andHealthcare products RegulatoryAgency [18].
The data demonstrate that there were a number of
recognised risk-factors (Box 1) in the prescribing habits of
clinicians at discharge that could contribute to a large
unused pool of opioids in the community. This reservoir of
opioids in the community could then be available for opioid
diversion, opioid misuse and predisposition to persistent
postoperative opioid use and opioid-induced ventilatory
impairment.
In the USA, the three most important modifiable risk-
factors for persistent postoperative opioid use are the use of
modified-release opioids, long duration of initial
prescriptions and repeat prescriptions [10]. The present
study has demonstrated that these three factors were
present in prescribing practices in England. Ten percent of
previously opioid na€ıve patients were discharged with these
medicines, 33.5% of patients prescribed opioids at
discharge did not have a specified duration and 13 of the 14
centres did not inform general practitioners that the opioids
should not become repeat prescriptions.
Moreover, transdermal fentanyl was also used
occasionally. This is especially disconcerting as the
summary of product characteristics of transdermal fentanyl
explicitly states that postoperative pain is a contra-
indication as “there is no opportunity for dose titration
during short-term use and because serious or life-
threatening hypoventilation could result” [27]. This stance is
Table 2 Pre-operative analgesic use. Oral morphine equivalent doses (OMED) are based on total number of patients on opioid





Major or complex-major surgery
n = 342
Regular intervals When required Regular intervals When required
Paracetamol 24 (15.3%) 10 (6.4%) 67 (19.6%) 25 (7.3%)
NSAID 8 (5.1%) 4 (2.6%) 10 (2.9%) 1 (0.3%)
Other adjuvants 25 (15.9%) 2 (1.3%) 29 (8.5%) 1 (0.3%)
Opioid 20 (12.7%) 13 (8.3%) 35 (10.2%) 21 (6.1%)
OMED;mg.day1 31 (16–35.5 [8–200]) 16 (12–40 [4–70]) 31 (16–45 [10–140]) 31 (16–40 [4–80])
NSAID, non-steroidal anti-inflammatory drug.
Figure 1 Box plot demonstrating variations in pre-admission and at discharge oralmorphine equivalent doses in opioid
na€ıve and opioid-tolerant patients undergoing intermediate andmajor or complexmajor surgery. Solid lines = medians,
boxes = IQR, whiskers = range excluding outliers and dots = outliers.
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reinforced by the recent drug safety update from the
Medicines and Healthcare products Regulatory Agency
[18]. Equally worrying was the use of ‘when required’
modified-release opioids. This is also explicitly discouraged
in the summary of product characteristics of modified-
release oral opioid preparations [28] and can only be
considered as dangerous practice because of the lack of
opportunity for dose titration [29].
The Medicines and Healthcare products Regulatory
Agency now advises that before starting treatment with any
opioid, a discussion should occur to agree a treatment
strategy and plan for end of treatment with the patient in
order to minimise the risk of dependence [18, 30]. This is
now highlighted in the summary of product characteristics
of all opioids [27, 28, 31]. The fact that the institutional data
(Table 5) showed that hospitals did not have formal
guidelines for discharge analgesia, and that doctors had no
formal training on discharge analgesia prescribing, coupled
with the fact that the advice from the Medicines and
Healthcare products Regulatory Agency was only published
in September 2020 [18], suggests that patients would not
have received this important weaning and deprescribing
information.
The reverse pain ladder is increasingly being
recommended as a concept to aid opioid weaning and
deprescribing [8, 29, 32]. It utilises a stepwise reduction in
analgesics, with ‘when required’ immediate-release opioids
weaned first, and then finally stopping the regular simple
analgesics (paracetamol and non-steroidal anti-
inflammatory drugs). The data from the present study
(Table 3) suggest that the reverse pain ladder was not being
used to aid weaning of opioids. Furthermore, compound
Table 3 Analgesia prescribed at discharge. Oral morphine equivalent doses (OMED) are based on total number of patients on










required Regular intervals When required
Analgesia prescribed at discharge 75 (47.8%) 56 (35.7%) 182 (53.2%) 139 (40.6%)
Type of analgesicmedicines
Paracetamol 46 (29.3%) 18 (5.3%) 138 (40.4%) 52 (15.2%)
NSAID 10 (6.8%) 7 (4.5%) 13 (3.8%) 4 (1.2%)
Codeine or dihydrocodeine 9 (5.7%) 20 (12.7%) 25 (7.3%) 26 (7.6%)
Compoundanalgesicsa 7 (4.5%) 8 (5.1%) 0 0
Other analgesic adjuncts 23 (14.6%) 2 (1.3%) 39 (11.4%) 0
Morphine sulphate oral solution 3 (1.9%) 10 (6.4%) 1 (0.3%) 38 (11.1%)
Tramadol 6 (3.8%) 8 (5.1%) 10 (2.9%) 19 (5.6%)
Immediate-release oxycodone 0 5 (3.2%) 0 25 (7.3%)
Modified-releasemorphine sulphate
(all patients)
7 (4.5%) 5 (3.2%) 21 (6.1%) 6 (1.8%)
Modified-releasemorphine sulphate
(opioid na€ıve patients)
5 (3.2%) 5 (3.2%) 13 (3.8%) 5 (1.5%)
Modified-release oxycodone (all patients) 4 (2.6%) 0 15 (4.4%) 0
Modified-release oxycodone
(opioid na€ıve patients)
3 (1.9%) 0 15 (4.4%) 0
Transdermal fentanyl (all patients) 1 (0.6%) 0 2 (0.6%) 0
Transdermal fentanyl (opioid na€ıve
patients)
1 (0.6%) 0 2 (0.6%) 0
Totalmodified-releasepreparations to
opioid na€ıve patientsb
9 (5.7%) 5 (3.2%) 30 (8.8%) 5 (1.5%)
Total on any opioids 33 (21.0%) 47 (29.9%) 74 (21.6%) 109 (31.9%)
OMED;mg.day1 31 (30–40 [8–160]) 40 (30–90 [4–320]) 30 (16–40 [4–360]) 60 (40–150 [12–480])
NSAID, non-steroidal anti-inflammatory drug.
aCompoundanalgesics including co-codamol and co-dydramol.
bTotalmodified-release preparations ofmorphine, oxycodone, tramadol and fentanyl to opioid na€ıve patients.
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analgesics were also being prescribed at discharge, both
for regular and ‘when required’ use. The use of compound
analgesic preparations that contain a simple analgesic (such
as aspirin or paracetamol) with an opioid component
reduce the scope for effective titration of the individual
components [20]. Consequently, they hinder opioid
deprescribing and are not recommended [8, 20].
Our data further highlight that the amount of opioids
prescribed at discharge was not category-specific, as
patients received similar amounts of opioid for open and
minimally invasive procedures, and for intermediate and
major or complex major procedures. The prescription of
excess opioids can be considered as poor practice for two
main reasons. It increases the risk of persistent
postoperative opioid use in the patient [10] as well as the
pool of opioids available in the community that can then be
used illicitly through opioid diversion. This reservoir has
been demonstrated to be a risk-factor in family and friends
developing opioid misuse issues [8]. Unfortunately, in the
hospitals studied there were no policies or guidelines to
ensure patients are informed how to safely dispose of
unused opioids.
Table 4 Logistic regression of opioid prescription at discharge. Values areORor 95%CI.
UnadjustedOR
(n = 499) 95%CI p value
Adjusted
OR
n = 499 95%CI p value
Sex
Female 1.00 1.00
Male 0.82 0.58–1.17 0.272 0.79 0.530–1.170 0.236
Age (years)
18–64 1.00 1.00
65–74 0.42 0.27–0.64 0.34 0.210–0.540
≥ 75 0.35 0.22–0.56 < 0.001 0.29 0.170–0.490 <0.001
Charlson comorbidity index
0 1.00 1.00
1–2 0.73 0.48–1.11 0.74 0.44–1.24
≥ 3 0.70 0.44–1.10 0.218 0.84 0.45–1.55 0.846
Arthritis
No 1.00 1.00
Yes 0.93 0.57–1.52 0.769 1.00 0.59–1.72 0.991
Mental health issues
No 1.00 1.00
Yes 0.83 0.46–1.53 0.555 0.69 0.36–1.33 0.270
Malignancy status
Benigndisease 1.00 1.00
Cancer 0.89 0.63–1.27 0.531 1.26 0.72–2.21 0.421
Pre-operativemedicines 1.00




Major or complexmajor 0.84 0.71–1.00 0.661 0.85 0.52–1.41 0.531
Surgical approach
Open 1.00 1.00
Minimally invasive 0.95 0.66–1.35 0.759 0.94 0.63–1.39 0.746
Length of stay; days
0–4 1.00 1.00
5–7 days 1.08 0.70–1.68 1.12 0.67–1.84
≥ 8 days 1.38 0.91–2.09 0.302 1.54 0.95–2.49 0.089
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With the increasing awareness of the dangers of post-
discharge opioidmisuse, there are now several national and
international consensus guidelines with broadly similar
recommendations [8, 26, 29, 33]. These include regular
simple analgesics, limited duration immediate-release
opioid to be titrated to promote mobilisation with a
duration that is appropriate for the surgery and the dose
appropriate for the patient’s age, avoidance of modified-
release formulations, strategies to prevent opioid diversion
and the need to ensure patients are aware of the need to
stop their opioids as well as safely disposing of unused
opioids.
This multicentre study included 14 institutions of
varying capacity across England, providing a representative
sample of the breadth of clinical practice for prescribing
analgesia at discharge after general surgical operations.
Only patients undergoing intermediate and major or
complex major surgery were included in order to capture
those most likely to require opioid analgesia at discharge.
However, the retrospective nature of this study and the
restriction to case selection, may also have introduced bias
as consecutive cases may not have been included. This was
despite each site ensuring that 25% of their submitted data
were verified locally. Additionally, the study only reflects
prescription practice at discharge in general surgery and
not the full spectrum of surgical specialties, especially those
where pain management is central to both patient
presentation and surgical outcome, such as orthopaedic
surgery. Nonetheless, by identifying a pattern of poor
prescribing practices and a lack of guidance and formal
training at individual institutions, this study highlights
opportunities for improvement in opioid-prescribing
practices in England.
This study has demonstrated there were aspects of
practice related to opioid prescribing at discharge that were
haphazard and known to contribute to opioid misuse. It has
also been demonstrated that there was a lack of guidance
and formal training at individual institutions. Now that it is
recognised that surgery is a risk-factor for persistent
postoperative opioid use in the UK [13], there is an urgent
need for organisations and clinicians to implement changes
in practice to improve opioid stewardship to reduce the risk
of opioid-related harm in adult surgical patients. Controlled
drug accountable officers and controlled drugs local
intelligence networks have statutory duties in promoting
opioid stewardship [34] and they provide an ideal conduit to
help implement the guidance of the Medicines and
Healthcare products Regulatory Agency [18] and other
aspects of opioid stewardship [35]. Nevertheless additional
resources will be needed to implement and sustain opioid
stewardshipprogrammes [30].
Table 5 Site questionnaire responses. Values are number.
Yes
n = 14
Are there any formal guidelines for discharge
analgesia at your trust/hospital site?
0
Dodoctors/prescribers have any formal trainingon:
a. Discharge analgesia prescribing? 0
b. Routine avoidanceof discharge
opioid analgesia prescription for > 7 days?
1
c. Routine avoidanceof compoundanalgesics? 0
d. Routine avoidanceofmodified-release opioid
preparations to previously opioid na€ıve patients?
2





Arepatients encouraged to purchase
their own simple analgesia on discharge,
rather than it beingdispensed
(e.g. paracetamol/ibuprofen)?
11
Are patients given advice on disposal
of unusedopioids?
0
Box 1 Examples from the current study of good
practice and deviation from national and
international guidelines [8, 26].
Goodpractice
• Regular simple analgesics such as paracetamol and
non-steroidal anti-inflammatory drugs
• Limited duration of ‘when required’ immediate-
release opioid tablets
• Age-related dosing of opioids
Deviation fromnational and international guidelines
• The use of ‘when required’ simple analgesics rather
than at regular intervals
• The use of modified-release opioid preparations in
patients not previously on thesemedicines
• The use of compound analgesic preparations
• The use of immediate-release opioids at regular
intervals rather than ‘when required’
• Not stating the duration for which analgesics should
be taken
• The use of transdermal fentanyl
• The lack of local opioid stewardship policies
(duration; deprescribing advice; disposal of unused
medicines; avoidance of repeat prescriptions)
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